Reviewing Microbot Medical (NASDAQ:MBOT) & RxSight (NASDAQ:RXST)

Microbot Medical (NASDAQ:MBOT) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Profitability

This table compares Microbot Medical and RxSight’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
RxSight	-36.58%	-17.01%	-15.12%

Insider & Institutional Ownership

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Microbot Medical and RxSight”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	$105,000.00	1,129.01	-$13.14 million	($0.26)	-6.79
RxSight	$127.48 million	1.75	-$38.94 million	($1.13)	-4.77

Microbot Medical has higher earnings, but lower revenue than RxSight. Microbot Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Microbot Medical and RxSight, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	1	2	1	2.60
RxSight	3	7	2	0	1.92

Microbot Medical presently has a consensus target price of $6.62, suggesting a potential upside of 275.35%. RxSight has a consensus target price of $8.89, suggesting a potential upside of 65.07%. Given Microbot Medical’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Microbot Medical is more favorable than RxSight.

Risk and Volatility

Microbot Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About RxSight

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.